Skip to main content

Congenital Atransferrinemia

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
Human apotransferrinPhase 21 trial
Active Trials
NCT01797055Active Not Recruiting5Est. Jan 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Prothya BiosolutionsHuman apotransferrin

Clinical Trials (1)

Total enrollment: 5 patients across 1 trials

Apotransferrin in Atransferrinemia

Start: Dec 2010Est. completion: Jan 20285 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.